MicroPort CardioFlow Announces First Commercial Implantations of AnchorMan® Left Atrial Appendage Closure System in Portugal
Porto, Portugal - September 16, 2026 — MicroPort CardioFlow announced the first two commercial implantations of its AnchorMan® Left Atrial Appendage Closure System in Portugal, marking the system’s entry into its fifth European country.
Left atrial appendage closure (LAAC) is a device-based treatment strategy for stroke prevention in selected patients with atrial fibrillation.1
The procedures were performed at Hospital de Santo António in Porto, part of Unidade Local de Saúde de Santo António (ULS Santo António). They were led by Dr. João António Brum da Silveira, former president of the Portuguese Association of Interventional Cardiology (APIC), alongside his clinical team.
Post-procedural assessments confirmed appropriate device positioning in both cases, with no residual shunts or clinical complications reported at the time of assessment.
“Our experience using the AnchorMan® system has been very positive,” said Dr. João António Brum da Silveira. “Its semi-closed structural design balances strong anchoring force and safety, the delivery system operates smoothly, and the release mechanism is clear and controllable, which gives operators greater confidence. I look forward to applying this innovative device to more patients in Portugal moving forward."
The commercial introduction of AnchorMan® in Portugal further expands the system’s presence in Europe as MicroPort CardioFlow continues to develop its structural heart portfolio internationally.
About MicroPort CardioFlow
MicroPort CardioFlow Medtech Corporation (HKEX: 02160.HK, an associated company of MicroPort Scientific Corporation; HKEX: 00853) develops innovative technologies for structural heart disease and cardiac rhythm management. With roots in the development of therapies for structural heart disease, the company holds a leading position in China's TAVI market and has built one of the broadest portfolios in the segment.
CardioFlow now combines its structural heart business with MicroPort CRM’s more than 60 years of rhythm management expertise, including 12 core development programs and a global portfolio of over 40 marketed products across pacemakers and ICDs. Together these form an integrated platform spanning structural heart intervention and cardiac rhythm management with a unique synergy to address heart failure.
By providing physicians and patients with innovative, full-cycle cardiac health management, the company is dedicated to building a leading enterprise of emerging technologies in cardiac diagnosis and therapy.
More information is available at: https://cf.microport.com/
Regulatory Disclaimer
AnchorMan® has been approved by the National Medical Products Administration (NMPA) in China, is CE marked in the European Union, and is approved in Argentina and Colombia. It is currently commercially available in China, in selected European countries including Portugal and in the Latin American countries listed above.
Regulatory status, intended use/indications and availability vary by country or region, and the product may not be approved or available in your country. AnchorMan® is not cleared or approved by the U.S. FDA and is not available for sale in the United States. This information is not intended to promote the use of the product where it is not authorized. HCPs should refer to applicable local regulatory requirements and to the applicable Instructions for Use. Please contact your regional representative for information on local availability.
Information current as of November 3, 2026.
Reference
- Van Gelder IC, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2024;45(36):3314–3414.
MicroPort Forward-Looking Statements
For purposes of this statement, "MicroPort" refers to MicroPort Scientific Corporation (HKEX: 00853) and, where the context requires, one or more of its direct and indirect subsidiaries, affiliates, and other entities under its control, including the business units and operations referenced in this press release. Statements in this press release concerning associated companies, joint ventures or third-party partners are based on information available to MicroPort and should not be interpreted as statements made by, or on behalf of, those entities.
This press release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and include, among other things, statements regarding the development, clinical evaluation, regulatory review and approval, commercialization and market adoption of MicroPort products and technologies; anticipated clinical, operational or commercial benefits; market opportunities; business and geographic expansion; and MicroPort's strategies, plans, objectives, expectations, projections and estimates. Such statements may be identified by words such as "expects," "anticipates," "believes," "intends," "estimates," "plans," "projects," "may," "will," "could," and similar expressions.
Forward-looking statements are based on current expectations, assumptions and information available as of the date of this press release and are subject to known and unknown risks and uncertainties, many of which may be difficult to predict or beyond MicroPort's control. These may include, among others: the outcomes and timing of research and development activities, clinical studies and regulatory processes, including submissions, reviews, decisions and the obtaining, maintenance, expansion or renewal of approvals, clearances and registrations, product safety, quality, recalls or manufacturing issues, product liability claims, changes in laws, regulations, healthcare, pricing and procurement policies (including centralized or volume-based procurement programs) or reimbursement environments, market acceptance, competition, pricing pressure, and commercial performance, supply-chain disruptions and dependence on suppliers, distributors, collaboration partners and other third parties, the ability to obtain, maintain and enforce intellectual property rights, as well as intellectual property matters, disputes or litigation, cybersecurity, information security and data protection risks, compliance with applicable anti-corruption, export control, sanctions and healthcare industry laws and regulations, access to financing, currency fluctuations, tariffs, trade restrictions and other international trade measures, and general economic, industry, market or geopolitical conditions.
For additional information regarding risks and uncertainties, readers should refer to the annual and interim reports and other public disclosures of MicroPort Scientific Corporation and, where applicable, any listed subsidiary whose securities are publicly traded.
Actual results may differ materially from those expressed or implied in any forward-looking statement. There can be no assurance that products or technologies under development will successfully complete clinical evaluation, obtain or maintain regulatory approvals, clearances or registrations in any particular jurisdiction, be commercialized within anticipated timelines or at all, or achieve anticipated clinical or commercial outcomes.
Forward-looking statements speak only as of the date of this press release and are based on the assumptions and information available as of such date. In light of the risks, uncertainties and assumptions described above, readers are cautioned not to place undue reliance on such statements. Except as required by the SFO, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, or any other applicable law or regulation, MicroPort undertakes no obligation to publicly update or revise any forward-looking statement to reflect new information, future events or otherwise.